BRPI0908474A2 - métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora - Google Patents

métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora

Info

Publication number
BRPI0908474A2
BRPI0908474A2 BRPI0908474A BRPI0908474A BRPI0908474A2 BR PI0908474 A2 BRPI0908474 A2 BR PI0908474A2 BR PI0908474 A BRPI0908474 A BR PI0908474A BR PI0908474 A BRPI0908474 A BR PI0908474A BR PI0908474 A2 BRPI0908474 A2 BR PI0908474A2
Authority
BR
Brazil
Prior art keywords
methods
ion exchange
exchange chromatography
gel filtration
pox virus
Prior art date
Application number
BRPI0908474A
Other languages
English (en)
Inventor
Yelin Xiong
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40956580&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of BRPI0908474A2 publication Critical patent/BRPI0908474A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0908474A 2008-02-12 2009-02-12 métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora BRPI0908474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6548408P 2008-02-12 2008-02-12
PCT/CA2009/000141 WO2009100521A1 (en) 2008-02-12 2009-02-12 Methods using ion exchange and gel filtration chromatography for poxvirus purification

Publications (1)

Publication Number Publication Date
BRPI0908474A2 true BRPI0908474A2 (pt) 2016-07-26

Family

ID=40956580

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908474A BRPI0908474A2 (pt) 2008-02-12 2009-02-12 métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora

Country Status (11)

Country Link
US (1) US20110165645A1 (pt)
EP (1) EP2240573A4 (pt)
JP (2) JP2011511640A (pt)
KR (1) KR20100113159A (pt)
CN (1) CN102257134B (pt)
AU (1) AU2009214768B2 (pt)
BR (1) BRPI0908474A2 (pt)
CA (1) CA2713891A1 (pt)
IL (1) IL207460A0 (pt)
MX (1) MX2010008970A (pt)
WO (1) WO2009100521A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760465A1 (en) 2009-05-12 2010-11-18 Transgene Sa Method for orthopoxvirus production and purification
BR112012026095A2 (pt) * 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
DK2596099T3 (da) 2010-07-20 2020-02-24 Bavarian Nordic As Fremgangsmåde til høst af ekspressionsprodukter
CN108404453B (zh) 2010-07-30 2021-01-05 Emd密理博公司 层析介质和方法
US9957485B2 (en) * 2012-04-08 2018-05-01 Inventprise, Llc Systems and methods for virus propagation in cell cultures for vaccine manufacture
CN105316296A (zh) * 2014-06-13 2016-02-10 亚宝药业太原制药有限公司 一种纯化腺病毒颗粒的方法
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
EP3188816B1 (en) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatography media comprising discrete porous bundles of nanofibrils
KR102582192B1 (ko) * 2014-12-05 2023-09-25 후지필름 가부시키가이샤 Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10954492B2 (en) * 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
CN105219741A (zh) * 2015-08-24 2016-01-06 深圳市百恩维生物科技有限公司 一种大规模获得高纯度、高活性慢病毒的工艺方法
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
RU2768045C2 (ru) * 2016-07-21 2022-03-23 Спарк Терапьютикс, Инк. СПОСОБ ПОЛУЧЕНИЯ ЧАСТИЦ РЕКОМБИНАНТНОГО АДЕНОАССОЦИИРОВАННОГО ВИРУСНОГО ВЕКТОРА (rAAV)
MX2019002495A (es) * 2016-09-01 2020-02-17 Takeda Vaccines Inc Metodos para producir virus para la produccion de vacunas.
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN106754346A (zh) * 2016-12-12 2017-05-31 厦门华厦学院 Dna微提取***及dna微提取方法
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
CN107485891B (zh) * 2017-07-20 2020-04-21 上海药明生物技术有限公司 改良的层析装置及其用于连续流层析的方法
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
CN108159411A (zh) * 2018-01-11 2018-06-15 江苏中慧元通生物科技有限公司 一种流感病毒亚单位疫苗纯化方法及其应用
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
CN110241093A (zh) * 2019-06-17 2019-09-17 深圳源兴基因技术有限公司 一种重组痘病毒的纯化方法
CN112143693A (zh) * 2019-06-28 2020-12-29 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
MX2022011071A (es) 2020-03-12 2022-09-23 Bavarian Nordic As Composiciones que mejoran la estabilidad del poxvirus.
CN111876392A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产病毒载体的方法
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
CN114544815B (zh) * 2022-03-01 2023-10-27 中牧实业股份有限公司 一种山羊痘病毒的定量检测方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
CN115261341B (zh) * 2022-09-05 2024-03-22 东曜药业有限公司 一种澄清溶瘤痘苗病毒收获液的方法
CN115873810B (zh) * 2022-12-26 2024-02-09 苏州良辰生物医药科技有限公司 一种鼠白血病病毒的纯化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
CN1289663C (zh) * 2001-12-20 2006-12-13 巴法里安诺迪克有限公司 从感染细胞中回收和纯化痘病毒的方法
DE10232828A1 (de) * 2002-07-19 2004-02-05 Goldschmidt Ag Verwendung von Antioxidantien in strahlenhärtbaren Beschichtungsmassen für die Herstellung von abhäsiven Beschichtungen
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
CA2555412C (en) * 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
US20090042274A1 (en) * 2004-07-27 2009-02-12 Genomidea Inc. Method of Purifying Virus Envelope
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
AU2009214768A1 (en) 2009-08-20
WO2009100521A1 (en) 2009-08-20
JP2011511640A (ja) 2011-04-14
US20110165645A1 (en) 2011-07-07
AU2009214768B2 (en) 2015-01-22
IL207460A0 (en) 2010-12-30
KR20100113159A (ko) 2010-10-20
JP5898261B2 (ja) 2016-04-06
CN102257134A (zh) 2011-11-23
EP2240573A1 (en) 2010-10-20
JP2014138622A (ja) 2014-07-31
CN102257134B (zh) 2014-03-05
MX2010008970A (es) 2011-05-30
EP2240573A4 (en) 2011-08-31
CA2713891A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
BRPI0908474A2 (pt) métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora
BRPI0812206A2 (pt) Métodos para melhorar o desempenho de proteínas
BR112013013668A2 (pt) moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos
CL2015000148A1 (es) Inmunoglobulina g variante porque comprende dos o mas sustituciones de aminoácidos; composición farmacéutica y kit que comprenden dicha inmunolobulina; uso de dicha inmunoglobulina para tratar tumor
BRPI0810740A2 (pt) Sistema de conversão de polarização e método para projeção esteroscópica
BR112013008738A2 (pt) processos para purificação de proteínas
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
DK2848625T3 (da) Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
BRPI0910449A2 (pt) Processo para purificação de álcool de fermentação
BRPI1013347A2 (pt) derivados de quinazolina modulantes da quinase jak e métodos para o uso dos mesmos
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0915825A2 (pt) proteínas de ligação à prostaglandina e2 usos das mesmas
BRPI0919250A2 (pt) métodos para a purificação de vírus
DK2526114T3 (da) Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
DK2061803T4 (da) Fremgangsmåde til oprensning af fc-holdige proteiner
BRPI0921911A2 (pt) métodos e sistemas com estruturas de quadro para melhor coexistência de canais adjacentes
BRPI0921106A2 (pt) biocombustível e processo para preparação de biocombustível
FI20086218A (fi) Menetelmä lämmönvaihtoa varten, järjestelmä ja käyttö
DK2307844T3 (da) Indspændingssystem
BRPI0817257A2 (pt) Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
DK2361388T3 (da) Fremgangsmåder til karakterisering af molekyler
BRPI0913833A2 (pt) uso de corantes ácidos
BR112013014751A2 (pt) sistema de manta para esterilização e métodos de uso
BRPI0811132A2 (pt) Preparação de catalisadores de paládio-ouro

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]